Centre of Reproductive Medicine and Andrology, Department of Clinical and Surgical Andrology, University Hospital Münster, Münster, Germany.
UroEvidence, Deutsche Gesellschaft für Urologie, Berlin, Germany.
Urol Int. 2021;105(3-4):181-191. doi: 10.1159/000511245. Epub 2021 Jan 22.
We developed the first German evidence- and consensus-based clinical guideline on diagnosis, treatment, and follow-up of germ cell tumours (GCT) of the testes in adult patients. We present the guideline content in 2 separate publications. The present second part summarizes therecommendations for the treatment of advanced disease stages and for the management of follow-up and late effects.
An interdisciplinary panel of 42 experts including 1 patient representative developed the guideline content. Clinical recommendations and statements were based on scientific evidence and expert consensus. For this purpose, evidence tables for several review questions, which were based on systematic literature searches (last search in March 2018), were provided. Thirty-one experts, who were entitled to vote, rated the final clinical recommendations and statements.
Here we present the treatment recommendations separately for patients with metastatic seminoma and non-seminomatous GCT (stages IIA/B and IIC/III), for restaging and treatment of residual masses, and for relapsed and refractory disease stages. The recommendations also cover extragonadal and sex cord/stromal tumours, the management of follow-up and toxicity, quality-of-life aspects, palliative care, and supportive therapy.
Physicians and other medical service providers who are involved in the diagnostics, treatment, and follow-up of GCT (all stages, outpatient and inpatient care as well as rehabilitation) are the users of the present guideline. The guideline also comprises quality indicators for measuring the implementation of the guideline recommendations in routine clinical care; these data will be presented in a future publication.
我们制定了首份基于证据和共识的德国临床指南,涵盖成人睾丸生殖细胞肿瘤(GCT)的诊断、治疗和随访。本指南内容分两部分发表,本文为第二部分,总结了晚期疾病阶段的治疗建议,以及随访和晚期效应的管理建议。
由 42 名跨学科专家组成的小组,包括 1 名患者代表,共同制定了指南内容。临床建议和声明基于科学证据和专家共识。为此,提供了针对多个审查问题的证据表,这些问题基于系统的文献检索(最后一次检索时间为 2018 年 3 月)。31 名有投票权的专家对最终的临床建议和声明进行了评分。
本文分别为转移性精原细胞瘤和非精原细胞瘤生殖细胞肿瘤(IIA/B 期和 IIC/III 期)、残留肿块的再分期和治疗、复发和难治性疾病阶段的治疗提供了建议。还涵盖了性腺外和性索/基质肿瘤、随访和毒性管理、生活质量方面、姑息治疗和支持治疗。
参与 GCT(所有阶段,门诊和住院治疗以及康复)的诊断、治疗和随访的医生和其他医疗服务提供者是本指南的使用者。指南还包括了用于衡量指南建议在常规临床护理中实施情况的质量指标,这些数据将在未来的出版物中呈现。